Omnicell (NASDAQ:OMCL) Stock Rating Upgraded by Wall Street Zen

Omnicell (NASDAQ:OMCL) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Several other research firms have also issued reports on OMCL. Weiss Ratings lowered Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, March 2nd. Benchmark restated a “buy” rating on shares of Omnicell in a research report on Friday, March 13th. Zacks Research upgraded Omnicell from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. UBS Group set a $60.00 price objective on Omnicell and gave the stock a “buy” rating in a research report on Friday, March 13th. Finally, KeyCorp lifted their price objective on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 28th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Omnicell presently has an average rating of “Moderate Buy” and an average target price of $59.86.

Omnicell Price Performance

OMCL opened at $42.80 on Friday. The stock’s 50 day simple moving average is $37.16 and its 200 day simple moving average is $39.58. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29. Omnicell has a 1 year low of $22.66 and a 1 year high of $55.00. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of 97.27, a PEG ratio of 1.08 and a beta of 0.96.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The business had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.02 million. During the same period last year, the company earned $0.26 EPS. Omnicell’s revenue for the quarter was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, analysts predict that Omnicell will post 1.34 earnings per share for the current year.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 7,405 shares of Omnicell stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the sale, the executive vice president directly owned 96,717 shares in the company, valued at approximately $3,355,112.73. This trade represents a 7.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.92% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Large investors have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new stake in shares of Omnicell in the 2nd quarter worth approximately $26,000. First Horizon Corp bought a new stake in shares of Omnicell in the 3rd quarter worth approximately $31,000. Farther Finance Advisors LLC lifted its stake in shares of Omnicell by 784.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock valued at $36,000 after purchasing an additional 1,036 shares during the period. Clearstead Advisors LLC lifted its stake in shares of Omnicell by 12,180.0% in the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after purchasing an additional 1,218 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Omnicell in the 4th quarter valued at approximately $58,000. 97.70% of the stock is currently owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.